{"id":64844,"date":"2026-05-09T15:09:34","date_gmt":"2026-05-09T07:09:34","guid":{"rendered":"https:\/\/flcube.com\/?p=64844"},"modified":"2026-05-09T15:09:35","modified_gmt":"2026-05-09T07:09:35","slug":"abb-bio-tech-secures-nmpa-clinical-approval-for-mrna-rsv-vaccine-addressing-critical-unmet-need-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64844","title":{"rendered":"Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China"},"content":{"rendered":"\n

Ab&B Bio-Tech Co., Ltd.<\/strong> (HKG: 2627<\/a>) announced it has received clinical trial approval from China’s National Medical Products Administration (NMPA)<\/strong> for its self-developed mRNA respiratory syncytial virus (RSV) vaccine<\/strong>. This milestone positions the company to address a significant unmet medical need in China, where RSV treatment currently relies on broad-spectrum antiviral drugs and symptomatic therapy rather than preventive vaccination.<\/p>\n\n\n\n

Disease Burden & Market Context<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Pathogen<\/strong><\/td>Respiratory syncytial virus (RSV)<\/td><\/tr>
Disease Impact<\/strong><\/td>Causes respiratory tract infections that can progress to bronchiolitis or pneumonia<\/td><\/tr>
High-Risk Populations<\/strong><\/td>Elderly individuals and patients with chronic diseases<\/td><\/tr>
Current Treatment in China<\/strong><\/td>Broad-spectrum antivirals and symptomatic therapy only<\/td><\/tr>
Prevention Gap<\/strong><\/td>No approved RSV vaccines currently available in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

RSV represents a substantial public health burden in China, with seasonal outbreaks affecting millions annually and contributing to significant hospitalization rates among vulnerable populations.<\/p>\n\n\n\n

mRNA Vaccine Technology Advantages<\/h2>\n\n\n\n

The approved mRNA RSV vaccine leverages platform technology demonstrated to provide:<\/p>\n\n\n\n